ClinicalTrialsFinder

Residual Cancer Clinical Trials in Orland Park, Illinois

1 recruitingOrland Park, Illinois

Showing 1–1 of 1 trials

Recruiting
Phase 2

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast CancerTriple-Negative Breast CancerCirculating Tumor DNA+1 more
Dana-Farber Cancer Institute40 enrolled7 locationsNCT04434040